The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Production of Helper Dependent Adenovirus Type 5 LRRK2 Expression Vectors
Study Rationale:
The LRRK2 gene has been implicated in Parkinson’s disease, but is too large to be expressed in viral vectors, a tool to modify cells. In order to study LRRK2... -
Target Advancement Program, 2016Biochemical Analysis and Structural Determination of LRRK2 with Kinase Inhibitors
Study Rationale:
Although pharmacological and surgical treatments are available to manage the symptoms of Parkinson’s disease (PD), none yet can slow down or stop the course of the... -
Improved Biomarkers and Clinical Outcome Measures, 2016Developing a Molecular Imaging Tool That Binds to Alpha-Synuclein and Inhibits Its Formation
Study Rationale:
Amyloid fibrils play a key role in Parkinson's disease (PD). Studying their formation from self‐assembled aggregates (protein clumps) would help aid the development of a valuable... -
Target Advancement Program, 2016Alpha-Synuclein Aggregates as an Inducer of Glial Senescence: Potential Role in Parkinson's Disease
Study Rationale:
Cellular senescence (deterioration) is a critical factor of biological aging that occurs in almost all peripheral tissues but little is known about its... -
Therapeutic Pipeline Program, 2016Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Study Rationale:
Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline... -
Target Advancement Program, 2016Genetic Modulation of LAMP-2A in PD Models
Study Rationale:
Brain cells use surveillance mechanisms to get rid of toxic proteins, such as mutant alpha-synuclein, that otherwise would accumulate and kill them. We have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.